Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage.
Cell–cell interaction
Interleukin-6
Signal transducer and activator of transcription 3
Small-cell lung cancer
Tumor-associated macrophage
Journal
Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
08
12
2022
accepted:
08
03
2023
medline:
19
4
2023
pubmed:
25
3
2023
entrez:
24
3
2023
Statut:
ppublish
Résumé
Tumor-associated macrophage (TAM)-derived IL-6 is involved in small-cell lung cancer (SCLC) progression and chemoresistance via the activation of signal transducer and activator of transcription 3 (STAT3) in the tumor microenvironment. This study aimed to identify natural compounds that suppress cell-cell interactions between TAMs and SCLC cells by inhibiting STAT3 activation. We used a library of natural compounds to identify candidate agents possessing anti-SCLC effects by inhibiting macrophage-induced tumor proliferation. SBC-3 and SBC-5, human SCLC cell lines, were used for in vitro experiments. Furthermore, we assessed the efficacy of these candidate agents in a murine xenograft model of human SCLC. Among the natural compounds examined, onionin A (ONA) inhibited IL-6-induced STAT3 activation and SCLC cell proliferation. ONA also reduced the secretion of IL-6 from macrophages and interfered with the direct effect of cell-cell interactions between macrophages and SCLC cells. Furthermore, ONA administration suppressed tumor progression in a tumor-bearing mouse model. ONA was identified as the most useful candidate for targeting cell-cell interactions between cancer cells and TAMs for anti-SCLC therapy.
Identifiants
pubmed: 36961655
doi: 10.1007/s13577-023-00895-6
pii: 10.1007/s13577-023-00895-6
pmc: PMC10110690
doi:
Substances chimiques
onionin A
0
Interleukin-6
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1068-1080Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K08603
Organisme : Japan Society for the Promotion of Science
ID : 22K08257
Organisme : Japan Society for the Promotion of Science
ID : 20H03459
Organisme : Japan Society for the Promotion of Science
ID : 16K09247
Organisme : Japan Society for the Promotion of Science
ID : 22K08284
Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2014 Mar 26;6(2):708-22
pubmed: 24675568
PLoS One. 2012;7(2):e30820
pubmed: 22319590
Cancer Res. 2018 Jun 15;78(12):3255-3266
pubmed: 29610117
Oncol Rep. 2011 Dec;26(6):1533-7
pubmed: 21922144
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
J Thorac Oncol. 2016 Apr;11(4):453-74
pubmed: 26829312
J Nat Prod. 2010 Jul 23;73(7):1306-8
pubmed: 20597533
J Thorac Dis. 2017 Nov;9(11):4185-4186
pubmed: 29268466
Cancer Immunol Immunother. 2019 Mar;68(3):489-502
pubmed: 30637473
J Cancer Res Clin Oncol. 2009 May;135(5):723-30
pubmed: 19002495
J Clin Oncol. 2018 Aug 10;36(23):2386-2394
pubmed: 29906251
Cancer Sci. 2010 Oct;101(10):2128-36
pubmed: 20860602
Front Mol Neurosci. 2018 Apr 03;11:98
pubmed: 29666569
Pathol Int. 2016 Sep;66(9):491-505
pubmed: 27444136
Ther Adv Med Oncol. 2010 Sep;2(5):301-7
pubmed: 21789142
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Front Immunol. 2022 Jul 28;13:959495
pubmed: 35967372
Mol Diagn Ther. 2011 Dec 1;15(6):347-52
pubmed: 22208386
Nat Rev Immunol. 2007 Jan;7(1):41-51
pubmed: 17186030
Mol Ther Oncolytics. 2021 Feb 06;20:470-483
pubmed: 33718595
J Thorac Oncol. 2021 Sep;16(9):1547-1558
pubmed: 33607312
Ann Oncol. 2010 May;21 Suppl 5:v220-2
pubmed: 20555085
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
pubmed: 22700443
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Sci. 2014 Jan;105(1):1-8
pubmed: 24168081
J Clin Exp Hematop. 2011;51(2):93-9
pubmed: 22104307
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Sci Rep. 2016 Jul 12;6:29588
pubmed: 27404320
Br J Cancer. 2009 Jun 16;100(12):1949-56
pubmed: 19455144
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
J Clin Exp Hematop. 2013;53(2):127-33
pubmed: 23995109
Lung Cancer. 2017 Apr;106:22-32
pubmed: 28285690
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Front Oncol. 2020 Dec 10;10:586580
pubmed: 33363016
Lung Cancer. 2009 Mar;63(3):315-21
pubmed: 18760859
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Aging (Albany NY). 2021 Oct 4;13(19):22883-22897
pubmed: 34607975
Cancer Sci. 2012 Dec;103(12):2165-72
pubmed: 22957741
Lung Cancer. 2013 Jun;80(3):256-62
pubmed: 23489559
Mol Nutr Food Res. 2016 Nov;60(11):2467-2480
pubmed: 27393711